Stephan Christgau
Executive Member
Bioinformatics & Systems Biology
Lysogene
France
Biography
Stephan Christgau, PhD, is the Investment Director of Novo Seeds. Prior to joining Novo Seeds, Dr. Christgau was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the financing and development of the company, taking the lead candidate drug through to Phase II testing for osteoporosis treatment. Previously Dr. Christgau worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S. Dr. Christgau holds a number of Board positions on European biotech companies including Adenium Biotech ApS, Aros Pharma ApS, Forendo Pharma OY and Galecto Biotech AB. He also serves as Chair for VentureCup, a non-profit entrepreneurship organization. Dr. Christgau obtained his MSc degree from the Technical University of Denmark in 1988 and his PhD degree in 1992 from the Technical University of Denmark, for a project in diabetes immunology, conducted at Hagedorn Research Institute and the University of California, San Francisco.
Research Interest
Bioinformatics & Systems Biology
